Meeting
2017 Gastrointestinal Cancers Symposium
CEA response and depth of response (DpR) to predict clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line cetuximab plus oxaliplatin-based chemotherapy: A sub-analysis of the JACCRO CC-05/06 trials.
Authors
Yu Sunakawa
Division of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan
Yu Sunakawa , Wataru Ichikawa , Akihito Tsuji , Tadamichi Denda , Yoshihiko Segawa , Yuji Negoro , Ken Shimada , Mitsugu Kochi , Masato Nakamura , Masahito Kotaka , Hiroaki Tanioka , Akinori Takagane , Satoshi Tani , Tatsuro Yamaguchi , Masahiro Takeuchi , Masashi Fujii , Toshifusa Nakajima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 648)
DOI
10.1200/JCO.2017.35.4_suppl.648
Abstract #
648
Poster Bd #
F22
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.
First Author: Federico Innocenti
Poster
2015 Gastrointestinal Cancers Symposium
Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
First Author: Sebastian Stintzing
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world evaluation of clinical outcomes and long-term survivors in patients with BRAF-V600E metastatic colorectal cancer.
First Author: William Phillips
Poster
2022 ASCO Annual Meeting
Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405.
First Author: Wu Zhang